Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Ketoreductase. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Patent CN117051052A reveals high-purity NEB-8 synthesis via MrADH. Offers supply chain reliability and significant cost reduction in pharmaceutical intermediate manufacturing processes.
Patent CN103554016B reveals enzymatic synthesis for high-purity API intermediates. Achieve substantial cost reduction and supply chain reliability with scalable green chemistry solutions.
Patent CN117402920A details a novel ketoreductase mutant for asymmetric reduction. This report analyzes cost reduction in chiral drug manufacturing and supply chain reliability for global buyers.
Patent CN115976130A reveals a novel enzymatic route for Rimegepant intermediate VI, achieving 90.1% yield and superior impurity control for reliable pharmaceutical supply chains.
Patent CN111705068A reveals a novel ketoreductase route for high-purity (R)-EHB, offering significant cost reduction and scalability for antibiotic intermediates.
Patent CN114807246A details high-efficiency enzymatic reduction for chiral alcohols, offering superior stereoselectivity and industrial scalability for pharmaceutical intermediates.
Patent CN103468757A details a green enzymatic reduction for Atazanavir intermediates, offering high purity and safer manufacturing for pharmaceutical supply chains.
Patent CN111662889B discloses a novel ketoreductase mutant enabling efficient synthesis of Darunavir intermediates with high substrate loading and reduced costs.
Patent CN112941114A reveals high-purity enzymatic route for chiral triols. Reduces production cost and improves supply chain reliability for global pharmaceutical intermediates manufacturing.
Patent CN115820782A reveals a green enzymatic route for 7-dehydrocholesterol intermediates, offering superior purity and yield for Vitamin D3 synthesis.
Novel enzymatic synthesis route for high-purity chiral alcohol intermediate. Reduces cost and improves safety for pharmaceutical manufacturing supply chains.
Patent CN1497048A details a biocatalytic route for chiral intermediates. Offers high ee and scalable production for pharma applications.
Patent CN111500652B reveals enzymatic route for florfenicol. Reduces waste and cost. Ideal for veterinary drugs supply chain optimization and high-purity manufacturing.
Patent CN114276280B reveals enzymatic route for chiral sulfonamide. Offers cost reduction and supply reliability for pharmaceutical intermediate manufacturing.